Back to search
FDAFDA · Food and drugs·Recall number Z-0761-2021

BD Phoenix PMIC-107: IVD is intended for the in vitro rapid identification (ID) of gram-positive bacteria from pure culture belonging to the genera Staphylococcus, Enterococcus, and other gram-positive cocci and gram-positive bacilli Catalog Number: 448417

Published January 6, 2021 · Recall initiated: December 8, 2020

Summary

FDA records medical device Class II recall Z-0761-2021, published January 6, 2021 and initiated December 8, 2020. Recalling firm: Becton Dickinson & Co.; Status: Terminated; Reported quantity: 103475 eaches; Lot: All unexpired lots UDI: 00382904484170. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

BD Phoenix Sulfamethoxazole-trimethoprim (SXT) Resistance, false resistant SXT result with S. aureus could lead to a potential loss of access to a preferred antibiotic regimen and potential reduction in effectiveness of treatment of the infection

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Becton Dickinson & Co.
Distributor
Nationwide
Lot
All unexpired lots UDI: 00382904484170
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was BD Phoenix PMIC-107: IVD is intended for the in vitro rapid identification (ID) of gram-positive bacteria from pure culture belonging to the genera Staphylococcus, Enterococcus, and other gram-positive cocci and gram-positive bacilli Catalog Number: 448417 recalled?

Yes. FDA published recall Z-0761-2021 on January 6, 2021. Reported hazard: BD Phoenix Sulfamethoxazole-trimethoprim (SXT) Resistance, false resistant SXT result with S. aureus could lead to a potential loss of access to a preferred antibiotic regimen and potential reduction in effectiveness of treatment of the infection

What should I do if I have this product?

Voluntary: Firm initiated · Letter